<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416221</url>
  </required_header>
  <id_info>
    <org_study_id>LXP-MD-106</org_study_id>
    <secondary_id>2005-3889(UCSD Number)</secondary_id>
    <nct_id>NCT00416221</nct_id>
  </id_info>
  <brief_title>PACEPro - Mood Management Pilot</brief_title>
  <official_title>Development and a Pilot Study of the PACEPRO Exercise and Mood Management Program in Depressed Patients on Escitalopram Oxalate (Lexapro)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <brief_summary>
    <textblock>
      Researchers at the University of California at San Diego (UCSD) are conducting a 12-week
      study to test the PACEPRO program. This program is designed to reduce depression by
      providing:

      Lexapro, an antidepressant medicine…Learn More Physical activity information and pedometer
      Mood management skills and a Mood Mastery Guide Personalized support from a Family Nurse
      Practitioner
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement visits will be conducted at the PACE office. The specific activities to be conducted at the baseline, 6 and 12 week assessment visits are listed below.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological Measures</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Height and weight</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist &amp; hip, circumference</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure and pulse</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activity level measured by wearing a monitor around the waist for 3 days (at baseline and 12 weeks only)</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interview/Survey Measures</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self report depressive symptoms</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report of moderate and vigorous physical activity for seven days</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report of TV viewing and recreational computer use for seven days</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report on readiness to make changes in physical activity and mood management behaviors</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Personal assessment of factors related to behavior change including: self-efficacy, social support, barriers to change, and use of behavior change skills, and the environment</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lexapro, an antidepressant medicine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical Activity</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mood Management Skills</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Personalized support from a Family Nurse Practitioner</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with mild to moderate depression

          -  Are willing to take the antidepressant Lexapro

          -  Can access and use Email and the Internet

          -  Are willing and able to be physically active

          -  Access to a primary care physician

        Exclusion Criteria:

        Subjects will be excluded from participation for the following reasons:

          -  Pregnancy or breastfeeding

          -  Narrow angle glaucoma

          -  Any uncontrolled medical condition or any medical condition which would represent a
             contraindication to Escitalopram Oxalate Lexapro® pharmacotherapy. Any concomitant
             non-psychotropic medications that the physician determines are a contraindication to
             Escitalopram Oxalate Lexapro® pharmacotherapy Bipolar disorder, or any psychotic or
             organic mental disorder or dementia

          -  History of intolerance or allergy to Lexapro, or of prior failed treatment for
             depression with Lexapro

          -  Current substance abuse or dependency

          -  Current active suicidal ideation

          -  Current use of herbal psychoactive treatments such as St. John's Wort

          -  Concurrent psychotropic medication is not permitted for 2 weeks prior to randomization
             (4 weeks in the case of fluoxetine) or at any point after

          -  Receipt of formal psychotherapy concurrently

          -  Inability, in the investigator's opinion, to comply with study procedures or
             assessments

          -  Inability to exercise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Patrick, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Pearson-Bennett, MSN, RN</last_name>
    <role>Study Director</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Professional Building</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2006</study_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <keyword>Depression</keyword>
  <keyword>Lexapro</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

